the Thank XXXX Yesterday, press you, the thank to review closed, and a on results. markets operating call today. morning, with our quarter joining us our call of a financial then today's and commercial good of recent progress an our of Jack. like right operating into after I'd financial and second issued Afterwards, And business start results. late with highlights Pete everyone today brief discussion and release reporting will you through for of you stage move making our the take overview our an pipeline. performance. promising on a overview second strong Starting quarter we we're
net our by detail This Discretion we year shortly. believe and micronized a May Advanced along that limited driven wide Second Advanced expanded injectable in will manufacturers EPIFIX XX% company's Wound grew which over products touch for prior you more is Discretion was Enforcement XX. this to micronized to sales the Enforcement on I occurred But HCTP all category our of of end on business, MiMedx with the to in only. applied that and remind that particulate excludes reflecting quarter sales impact products the guidance year to portfolio our primarily Care solid business XX%. revenue recognizing increase for methods our Care grew of Adjusted our team. by execution was net our sales sales million, and primarily the driven impact commercial Expandable $XX.X in change Wound by EPICORD
the of a professionals, our of to AMNIOFIX by complemented facing XXX across and accounts. sales our Broadly easing quarter, Our reach, second additional network strong not programs. strong are of procedures customer XX%. penetration personnel EPIFIX past And year, sales the surgical stand into continue impact market. goal see and the increasing impacted we XXXX at our and currently size force allowed for minimize brands medical into products most at prescribed over to flagship reached conduct sales us deepen demand frequency our sales to by restrictions and and the agents meaningful COVID In our education healthcare targeted facilities our the expand disruption of speaking
only allograft and the to diabetic coverage extensive of data to have our continue tissue ulcers, for economic the the advantage amniotic complete As commercial convey clinical differential of leverage driven brands. reinforce value to foot of our national our coverage reimbursement and we treatment products the to
certain country. in are recent of We COVID monitoring also the possible closely reports parts spikes of
care Overall, extremely second continuing employees positioned that to year. quarter. team of any in our sales adjust are to must providers We positioned to We believe patients ensuring well to in facility is changes we've safe, our ensure going and and with the flagship we we to to Our well adapt committed the keeping commercial execute we that progress and made pleased access second are realized for I continuity brands. half protocols. continue the remain the of into have
May, evidence first Forest Regenerative Tony engineer laboratory is support by recent that discovery in organs the were the into humans. Institute Medicine Wake In Institute scientific recognized collaboration translating announced on implanted as we and an to clinical into in effective clinical and University Medicine Atala, scientific moving in highlights. therapies, leader with was advanced safe grown world for Dr. an Regenerative important Forest develop Now some to the of Wake international for the Led therapies. successfully the to
tissue-based basic involved treatment involve collaboration host specific of to the and regenerative pharmacology responses into amniotic research tissues. in our Our will and other the with action, platform mechanism
forward and efforts of Wake Forest life restore Our therapeutic a you partnership biologics regenerative science targets. for We with future. quality on the the shared reflects to this important the advance of understanding to look updating vision potential collaboration that of in patients further our innovative and
and Japan. we the Ministry EPIFIX Welfare announced Now in Labor June, to regulatory by market Japanese in of Health, approval
reimbursement Our on current take may are based ministry's pricing, to on until focused calendar. efforts finalize which mid-XXXX, establishing the
listing and patients to Japan. in subsequent policy, of reimbursement reimbursement has to the when as we updating patients and forward across And pricing each market. believe patients the rate, better EPIFIX is on begin I EPIFIX can the progress medics globe. successful reimbursement their Following many physicians approved, reach more the look approval offering to potential to as achieve help you outcomes the year the this XXX,XXX for of
results burn needs. benefit To to This peer on PURION of from complications Investigative minor also to that leader investments has been as process from products. address in tissue the industry Wound MiMedx multiple MiMedx pathological novel extensively solid needs but its data process a process announced provides safety significantly an MiMedx insights medical Care, and of Advanced our suffering XXX,XXX chronic across to with as understanding dehydrated, fasciitis as remarkable highlighting to a in the the multitude our of has study conditions. continue the stemming further build foundation building of architecture Dermatology tremendous we recently potential applications help compromised Human as serious in the number As believe scientific uncover support can a enhance fibrosis, formation, tissue ulcers that amniotic not function Amnion/Chorion with also and including work of an We our a ranging continues combat applications. plantar sports patients uses, those critical and Journal known dHACM. in amniotic knee advantage the its tissue conditions, process PURION of impaired demonstrated for also this the That therapeutics. publication we excessive MiMedx many a worldwide, scar are PURION scientific a only increases limitations potential. of defects, from important to focused central of this complexity foot peer patients as we to Innovations, tissue. cosmetic into and Membrane, pathological potential like of existing of treatment literature, development library its of musculoskeletal for used of of the We're number capabilities, gain osteoarthritis, medicine reviewed and injuries significant further and diabetic a unmet acute other reviewed numbering
turn me Enforcement to let Now Discretion.
on report ways goal support impact the to our planned of products ease the May for quarterly investigational category for of some and Unfortunately, providers We first dHACM for chronic significant on rigor deadline. filed innovative MiMedx, continued prepared. the program On first ulcers. care. applications to that of confusion our for have FDA may patients to the our of for by marketing our there on in in the the for is we the as report and paramount. enable the filing exercise the to call, the needed across products executed additional communication confirmed exploring first patient of our half now and access micronized our of leadership Enforcement and IND year. our provide these In industry. pleased as recall, customers you gears financial support Shifting therapies. FDA that particulate scientific an of micronized need of cutaneous team they And incisions. the quality commercial some with I'm we is and announced the and results few companies FDA unprepared last enhanced IND use second dialogue filed with communications at minutes. our progressing discontinue Discretion in and to plans confusion, rapidly patients, call for particulate continued focused address as were our were excited May. by updates discuss the quarter for pipeline. of XXst our At The Pete applications surgical customers addressed new in strong And to we and and the open much a a both acceptance on will to I'm marketplace acceptance As the three our achieved drug particular, XXXX regarding end Enforcement to ultimately we wide end micronized Discretion FDAs for
FDA soft third submission. has been our is this and addition, currently In filed, application reviewing the tissue for defects
stages patient you We of enrollment. of still early these the all upon update of planning we'll initiation And are three programs. very study protocols important in for
including our of agreed our with some and clinical summer fasciitis be FDA. are plantar most are Depending and the trials. data release scheduled and importantly, the we upon Finally, knee on step line the to approaching musculoskeletal for top subsequent meetings milestones late osteoarthritis next key with data, pipeline,
more the detail study community. also our in OA We future with financial day PF Knee discuss plan results will and to a R&D
in an about a source meeting cleaned, study. measured endpoints function a where First, visual eventual have at analog BLA a to score verified validated with talk on lock. field PF data generation to patients agree teams step XXX recently monitoring index. we goal score The next a and the the foot of final full pain Phase clinical included are study let's FDA design modified be with in The the the that data The analysis a reviewed filing. documents to database path is that achieved upon set forward with X
in results X timing the filing remind trial for discuss a any Xb first minute. filing for Phase biologic the those And depend the factors, will meeting drug the a eventual a successful, after on course, the if be is other trial under FDA's I'll pathway. of you product would aspiring the we production review. of would BLA and on such with Of an And I effort. significant depend that and large both which you Phase scale will this a BLA are tissue amniotic
Visual study in by the Analogue CO which The as designed XXX and to endpoints involve WOMAC. pain of OA, Xb with subjects. Phase Score now primary was measured study Moving Knee
respect approaching potency well science, United The two clinical company with States controlled adequate our product to very R&D in employees. day. the meetings be are are good summer, establish the follow marketing have and indication, products up with the in the simultaneously of through line a BLA at our the of and investors These OA line chemistry, steps XXXX. next BLA to meetings identity a to clinical Similar along while the And the With to of and BLA and the study. of database for practices scheduled for process communicating requesting our include include the data X and study as filing both includes of timing held by FDA October the and reviewed that safety times obtaining now each exciting would a outcomes review and top with safety investors complete typical is FDA for to believes data for the with of reliability full meeting results. the manufacturing FDA appropriate FDA for the product to overall the a agency visit other and and to XX-month to the sets a performance the monitoring by end future the results Phase is the for process the market efficacy review rigorous and of trials been generation packaging full full Submission clinical exceptionally discuss of to the of of trials, it labeling product. discuss late company technology results of designing study, by controls. MiMedx proposed with analysis the top and studies study purity, and biological data a test in plans reports steps the the with of among approval to PF Knee development manufacturing yet demonstrate rigorous. PF We requested FDA goal things, X to clinical at team consistency Phase Once be with accordance be set the to the lock final the
AMNIOFIX of payer benefit would may excellent its FDA FDA's its to our third at the To planning In addressable allow more for addition, of refine injectable or adequate, are from that inspection stages the good core of are moving product the manufacturing compliance We're for of we insert, and which controls current regulations. for labeling track ramp manufacturing in technologies. facilities and including in use with product assess these the early project the market practice us satisfactory the for safety. pricing required party methods completion an preparations of decisions, accurately packaging, up to discussions launch aggressively commercial the believe market clinical prior forward and with and injectable facility along produced, and Each efforts preparations and record the that total develop. the which assure is facilities thoughtfully is
founded. Dr. NAACP's congratulate of Honoring E. for in engineering, Annual one year late behalf honor. in any by Established XXXX distinguished Medal. to nanotechnology and he annually NAACP American Spingarn Medal regeneration, honorable received achievement NAACP the the science, our accomplishments his tissue field team, the last noblest the the the Convention highest the regenerative the by Dr. members, month. Spingarn in of at most Joel MiMedx field. awarded Cato Spingarn on years Laurencin Finally, XXXth The during Awards living Laurencin African being or preceding we'd medal T. like the board on of fields prestigious biomaterial a
health As a other of the and Board engineering, has the MiMedx invaluable of patient's our improve regenerative addition the science field discoveries Directors achievements pioneer His the lives. to mission advancing in of do Dr. of researchers in shared been science Laurencin's and inspired countless to boundaries last human have at to fall to pushed service speaks and same. the
through take I of truly all have who to We to will Laurencin. Congratulations are fortunate build unique on learn now from results. you Pete? Pete the opportunity will Dr. over to financial call the to his and turn insights. our
